Gilead Sciences, Inc.
—- Market cap
- $179.56B
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $179.56B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: GILD stock price at discount vs LHX $144.81 current versus $197.41 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LHX's multiple
Implied fair value · at GILD's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
L3HARRIS TECHNOLOGIES, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
GILD vs ABBV
AMGEN INC
GILD vs AMGN
BRISTOL MYERS SQUIBB CO
GILD vs BMY
Merck & Co., Inc.
GILD vs MRK
PFIZER INC
GILD vs PFE
REGENERON PHARMACEUTICALS, INC.
GILD vs REGN
LOCKHEED MARTIN CORP
GILD vs LMT
NORTHROP GRUMMAN CORP /DE/
GILD vs NOC
BOEING CO
GILD vs BA
RTX Corp
GILD vs RTX
GENERAL DYNAMICS CORP
GILD vs GD
HEICO CORP
GILD vs HEI
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GILD can sustain its 22.3% ROIC and 28.9% net margin despite only 2.4% revenue growth, then owning GILD makes sense because the business quality is clearly stronger than LHX even though the current price is not cheap versus DCF or history.
LHX-implied valuation of $240.13 suggests an 82.9% upside to GILD's current price of $131.30, but that comparison is distorted by a very different LHX profile. GILD also trades inside its historical band and above the DCF range, which argues that the stock is not broadly mispriced on an absolute basis.
Supporting Metrics